Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 51Leukemia, Myeloid, Acute 45Neoplasm Metastasis 43Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 37Prostatic Neoplasms 30Multiple Myeloma 30Colorectal Neoplasms 27Pancreatic Neoplasms 26Melanoma 23Carcinoma, Renal Cell 23Ovarian Neoplasms 21Lymphoma 20Burkitt Lymphoma 19Triple Negative Breast Neoplasms 18Myelodysplastic Syndromes 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Urinary Bladder Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Fallopian Tube Neoplasms 14Carcinoma, Hepatocellular 14Oropharyngeal Neoplasms 13Glioma 13Sarcoma 12Mouth Neoplasms 12Carcinoma 12Astrocytoma 12

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Specimen Handling × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡